Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against Candida glabrata

Petra Schwarz, Ilya Nikolskiy, Éric Dannaoui, Frank Sommer, Gert Bange, Patrick SchwarzJournal of Fungi 2022 · DOI

TL;DR

This study investigated the in vitro synergistic effects of the antifungal drug isavuconazole and the flavonoid isoquercitrin against various Candida species. They found a promising synergistic interaction specifically against Candida glabrata, suggesting a potential new avenue for treating invasive candidiasis, a serious and often fatal infection.

What Problem Does This Paper Address?

Invasive candidiasis, a life-threatening fungal infection, poses a significant global health challenge due to its high mortality rate and the increasing emergence of antifungal resistance. While echinocandins are a first-line treatment, azoles like isavuconazole are used as step-down therapy. However, resistance to both drug classes is a growing concern, particularly in non-albicans species like Candida glabrata. This necessitates the exploration of novel therapeutic strategies, such as antifungal combinations, to enhance efficacy, reduce toxicity, and overcome resistance. This paper addresses the need for effective combinations by evaluating the synergistic potential of isavuconazole with isoquercitrin, a flavonoid with known antifungal properties, against a panel of clinically relevant Candida species.

Methods

The researchers employed a standard broth microdilution checkerboard technique, adhering to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. This method involves serially diluting two drugs in a microplate to create a grid of combinations. They then inoculated this grid with the fungal strains and measured growth inhibition.

To interpret the results, two primary analytical approaches were used:

  • Fractional Inhibitory Concentration Index (FICI): This is a common method to quantify drug interactions. It calculates a combined score based on the minimum inhibitory concentrations (MICs) of each drug when used alone and in combination.
  • FICI ≤ 0.5 indicates synergy.
  • 0.5 < FICI ≤ 4 indicates indifference.
  • FICI > 4 indicates antagonism.
  • Response Surface Analysis (RSA) based on the Bliss Independence Model: This is a more sophisticated, model-independent method that analyzes the entire dose-response surface of the microplate, not just the MICs. It compares the observed drug interaction to a theoretical surface assuming independent drug action. This method provides a more comprehensive view of the interaction across a range of drug concentrations. The SUM-SYN-ANT metric was used to quantify the synergy or antagonism.

Datasets

The study utilized a collection of 60 clinical Candida strains, comprising:

  • 10 Candida albicans
  • 30 Candida glabrata
  • 6 Candida kefyr
  • 5 Candida krusei
  • 4 Candida parapsilosis
  • 5 Candida tropicalis

These strains were sourced from international collections (American Type Culture Collection and Deutsche Sammlung von Mikroorganismen und Zellkulturen) and the Department of Microbiology at the University Hospital Marburg. The species identification was confirmed by sequencing the Internal Transcribed Spacer (ITS)1–5.8S-ITS2 region.

Key Insights and Ideas

  • Targeted Synergy: The most striking finding is the consistent synergistic interaction between isavuconazole and isoquercitrin specifically against Candida glabrata. This suggests that isoquercitrin can significantly boost the antifungal power of isavuconazole in this particular species.
  • Species-Specific Interactions: The combination showed indifference against other tested Candida species (C. albicans, C. krusei, C. kefyr, C. parapsilosis, and C. tropicalis). This highlights that antifungal synergy is not universal and can be highly dependent on the fungal species.
  • No Antagonism: A crucial and reassuring observation is that no antagonistic interactions were observed across any of the tested strains or species. This means that combining these drugs is unlikely to make the infection worse.
  • Methodological Discrepancies: The study noted a difference in synergy detection between the FICI and RSA methods for C. glabrata. While FICI indicated synergy in 100% of C. glabrata strains, RSA showed synergy in 60%. This discrepancy underscores the importance of choosing appropriate analytical methods and highlights the potential for different interpretations of drug interactions. The authors suggest the stringent threshold used in RSA might explain this.
  • Flavonoid Potential: Isoquercitrin, a naturally occurring flavonoid, demonstrates potential as an adjunct therapy in combating fungal infections, particularly when combined with established antifungals.

Key Results

  • Synergy against C. glabrata:
  • Using the FICI method, 100% of the 30 C. glabrata strains tested showed synergistic interaction with isavuconazole and isoquercitrin.
  • Using Response Surface Analysis (RSA), 60% of the C. glabrata strains exhibited synergy.
  • Indifference against other species: For C. albicans, C. krusei, C. parapsilosis, and C. tropicalis, the combination of isavuconazole and isoquercitrin showed indifferent interaction in all tested strains, regardless of the interpretation method.
  • No Antagonism: Antagonistic interactions were never observed for any of the tested strains.
  • MIC Ranges: Isavuconazole MICs ranged from 0.0005 to 1 µg/mL, while isoquercitrin MICs varied from 16 to 128 µg/mL, with some species showing no activity even at higher concentrations.

Limitations and Future Work

  • Molecular Resistance Mechanisms: The study acknowledges a limitation in not performing molecular determination of azole resistance or FKS gene mutations for the C. glabrata strains. This is particularly relevant given the known resistance mechanisms in this species.
  • EUCAST Breakpoints: The lack of defined EUCAST breakpoints and epidemiological cut-off values for isavuconazole against C. glabrata makes definitive interpretation of resistance challenging.
  • In Vivo Validation: The current study is purely in vitro. The authors explicitly state that these results warrant further animal experiments to validate the observed synergy and assess its clinical relevance.
  • Strain Specificity: While synergy was observed for C. glabrata, the discrepancy between FICI and RSA results suggests that further investigation into the optimal interpretation methods and thresholds might be beneficial. The authors also note that the interaction against C. albicans was indifferent, contrasting with a previous study that found synergy with fluconazole, suggesting strain-specific or azole-specific interactions.

Summary updated

Abstract

In vitro interactions of broad-spectrum azole isavuconazole with flavonoid isoquercitrin were evaluated by a broth microdilution checkerboard technique based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methodology for antifungal susceptibility testing against 60 <i>Candida</i> strains belonging to the species <i>Candida albicans</i> (<i>n</i> = 10), <i>Candida glabrata</i> (<i>n</i> = 30), <i>Candida kefyr</i> (<i>n</i> = 6), <i>Candida krusei</i> (<i>n</i> = 5), <i>Candida parapsilosis</i> (<i>n</i> = 4), and <i>Candida tropicalis</i> (<i>n</i> = 5). The results were analyzed with the fractional inhibitory concentration index and by response surface analysis based on the Bliss model. Synergy was found for all <i>C. glabrata</i> strains, when the results were interpreted by the fractional inhibitory concentration index, and for 60% of the strains when response surface analysis was used. Interaction for all other species was indifferent for all strains tested, whatever interpretation model used. Importantly, antagonistic interaction was never observed.
BibTeX
@article{schwarz2022synergistic,
  author = {Petra Schwarz and Ilya Nikolskiy and Éric Dannaoui and Frank Sommer and Gert Bange and Patrick Schwarz and Patrick Schwarz and Patrick Schwarz},
  title = {{Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against Candida glabrata}},
  journal = {Journal of Fungi},
  year = {2022},
  doi = {10.3390/jof8050525},
}
Figure